Webinar

The Role and Rationale for Oral Options in the Treatment of Metastatic Breast Cancer

Breast cancer oncologists explore more recent advances using oral chemotherapies to treat metastatic breast cancer.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Merrill H. Stewart, MD
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
EHA 2025 Congress Recap | Image Credit: Venngage
Ashley Yocum, PhD
Dr Matthew Matasar
Dr Xavier Leleu
Dr Marina Kremskayana
Dr Sundar Jagannath
Related Content
Democratic Doctors Caucus June 11 Press Conference
June 18th 2025

Democratic Doctors Caucus Reaffirms EMTALA Amid Trump's CMS Policy Reversal on Abortion Care

Giuliana Grossi
Democratic leaders assert the Emergency Medical Treatment and Labor Act (EMTALA) remains vital for emergency care, countering confusion from recent policy changes affecting abortion rights and patient safety.
Managed Care Cast
June 17th 2025

Managed Care Cast News Roundup: June 17, 2025

Giuliana Grossi
A quick roundup episode of major news and health policy developments from The American Journal of Managed Care.
A comprehensive home-based program integrating weekly telecounseling and individually tailored breathing exercise training reduced hospitalizations among patients with COPD. | Image credit: Ahmad - stock.adobe.com
June 18th 2025

Telehealth Model Reduces Hospital Admissions in COPD

Kimberly Rath, PharmD
Remote care reduced readmissions and improved functional outcomes in COPD in a recent study.
managed care cast logo
June 10th 2025

Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs

Brooke McCormick Julia D. Lucaci, PharmD, MS
Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
June 18th 2025

Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

Rose McNulty
Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging treatment norms.
FDA Approved
June 18th 2025

Twice-Yearly Lenacapavir Approval Marks Major Milestone in Prevention of HIV

Julia Bonavitacola
The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo